Samah W. Awwad
@SamahAwwad3
Followers
166
Following
664
Media
4
Statuses
122
Postdoc @SPjacksonGroup @CRUK_CI @Cambridge_uni. Interested in #DNAdamage #Replicationstress #Genomestability
Cambridge, England
Joined January 2019
Based on feedback from applicants, reviewers and broader research community, the ERC Scientific Council decided to make changes in the 2026–27 calls for proposal for research funding. More details from the ERC President 👉 https://t.co/09BiCl0Txu What’s your take? Tell us! 👇
3
52
140
Excited to be at #cshldnarep at CSHL this week! Looking forward to giving my talk this morning and connecting with other to discuss our fantastic science! If you too are attending feel free to reach out!
0
0
7
8 Greatest Laws I know at 40, I wish I knew at 20: 1.
57
2K
13K
Thrilled and excited to share our latest work published in #BloodJournal. We uncover how defective neutrophil clearance drives #myelofibrosis via immune checkpoint #CD24 in myeloproliferative neoplasms. The First Edition⬇️ https://t.co/CCmXK3OARr
8
2
14
Research Assistant (Jackson Group) (Fixed Term) @Cambridge_Uni
0
5
11
“To write for impact means to keep it as simple as possible.” Good read and very insightful. https://t.co/5WIzWZjHqa
7
569
2K
A BIG STUDY in Nature Medicine: Which food makes you age faster? Scientists looked at 105,000 people in 30 years. The statistics is impressive. The study is open-access, so everyone can read it. 📍 Findings: The diet that ROCKS: fruits, vegetables, whole grains, unsaturated
49
304
1K
Excited to share our preprint, work spearheaded by PhD student @jordancjwilson with Marciniak Lab @TheCIMR, @villunger & our @ERC_Research partners @jcornlab & @LoizouJoanna. This sheds light on the action of WEE1 inhibitors and their therapeutic use,
biorxiv.org
Inhibitors of the protein kinase WEE1 have emerged as promising agents for cancer therapy. In this study, we uncover synergistic interactions between WEE1 small- molecule inhibitors and defects in...
3
5
36
Great opportunity and great mentor!
🚨 Fully funded #PhD opportunity! 🚨 Passionate about cancer research? Join @MadziaCrossley's team to investigate how R-loop dysregulation contributes to cancer. 📍 Cambridge, UK 💰 Fully funded 📅 Apply by 24 March 2025 https://t.co/AzO4RB1OSZ
0
0
2
Don't miss this opportunity to learn about #CRISPR from world experts including Thijn Brummelkamp @NKI_nl, @durocher1, @erika_alden_d, @LeopoldParts @sangerinstitute and Weixin Tang @UChiChemistry. Bursary application deadline 14 Jan, abstract deadline 4 Feb. Tell your friends!
Make your mark on the future of #PrecisionMedicine at #CRISPR25 Showcase #CRISPR methods for modulating the genome at scale🧬 Submit an abstract by 4 February for an opportunity to build your professional profile at the forefront of a global community 📎 https://t.co/rfey5GRqje
0
6
16
This exciting novel discovery, published in @NatureComms, with contributions from the Balasubramanian lab @ChemCambridge, was supported by @CR_UK, @TheMarkFdn, @wellcometrust and @ERC_Research.
Happy to share our newly published article in Nature Communications! In this work, we uncover the novel role of KLF5 in sensitizing cells to ATR inhibition, identifying it as a synthetic lethal partner with the tumor suppressor ARID1A. @SPJacksonGroup
https://t.co/0bHKUUitvP
0
3
16
Huge thanks to our amazing collaborators for their essential contributions! #CancerResearch #ATR #SyntheticLethality
1
0
0
Happy to share our newly published article in Nature Communications! In this work, we uncover the novel role of KLF5 in sensitizing cells to ATR inhibition, identifying it as a synthetic lethal partner with the tumor suppressor ARID1A. @SPJacksonGroup
https://t.co/0bHKUUitvP
nature.com
Nature Communications - ATR inhibitors are being developed for treating cancers, but mechanisms that determine their efficacy are unclear. Here, the authors show that transcription factor KLF5 loss...
4
12
56
Now out in @GenomeMedicine @BioMedCentral. Transform your #crispr screens with "Exorcise", EXOme-guided Re-annotation of nuCleotIde SEquences, https://t.co/ekrZRkOf2d.
link.springer.com
Genome Medicine - CRISPR-Cas9 technology has revolutionised genetic screens and can inform on gene essentiality and chemo-genetic interactions. It is easily deployed and widely supported with many...
0
10
33
We are recruiting for a Research Assistant (Computing) (Fixed Term) @Cambridge_Uni
https://t.co/MVZUHDzQnT Please share
0
4
2
Two exciting opportunities for suitably qualified postgraduates/postdocs to join the Steve Jackson lab at the world renowned @CRUK_CI @Cambridge_Uni, https://t.co/OEog9BGuS2 and https://t.co/dL8MEl4PRf. Come join us!
0
14
28
With 3 approved epigenetic drug classes and many more under clinical investigation, epigenetic targets are gaining traction. Here, we take survey of developments and hurdles in targeting the cancer epigenome. Thank you @NatureCancer for the opportunity https://t.co/KH6Ijzpkll
nature.com
Nature Cancer - Stegmaier and colleagues provide a review on the latest development in targeting the cancer epigenome, give an overview of distinct drug classes, and discuss therapeutic...
1
73
207
SUMO/ubiquitin E3 ligase #TOPORS promotes #decitabine tolerance by removal of DNMT1-DNA crosslinks; while dCMP deaminase DCTD generates 5-aza-dUMP & exacerbates cytotoxicity indep. of DNA-protein crosslinks @cjcarnie et al @stingele_lab @SPJacksonGroup
https://t.co/Wq7xztvWSn
0
6
13